<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01516424</url>
  </required_header>
  <id_info>
    <org_study_id>D4906011</org_study_id>
    <nct_id>NCT01516424</nct_id>
  </id_info>
  <brief_title>Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone</brief_title>
  <official_title>A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Clinical
      trial to Investigate Blonanserin in Treatment of Schizophrenia when compared with Risperidone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Clinical
      trial to Investigate Blonanserin in Treatment of Schizophrenia when compared with Risperidone

      Trial drugs:

        -  Blonanserin group: Blonanserin tablets+Risperidone mimetic tablets

        -  Risperidone group: Risperidone tablets+Blonanserin mimetic tablets

      Objectives of Study :

      To evaluate the efficacy and safety of Blonanserin in treating schizophrenia
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in PANSS(Positive and Negative Syndrome Scale) Total Score at Week 8</measure>
    <time_frame>From baseline to the end of study、week 8(day 56)or before other antipsychotic taken.</time_frame>
    <description>Mean change in Positive and Negative Syndrome Scale total score from baseline to Week 8 at the end of treatment. PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. It have 30 evaluation items, which include 7 positive sub-scale, 7 negative sub-scale and 16 general psychopathology sub-scale on a score of 1 to 7. The total score is the sum of the 30 scale items. The minimum score is 30 and the maximum score is 210. Patient with PANSS total scores＜70 is the normal,but the scores＞120 is more serious.Change=(Week 8 Score - Baseline score)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in PANSS Subscale Score at the End of Treatment</measure>
    <time_frame>week 8</time_frame>
    <description>Mean Change in PANSS subscale score at the end of treatment at 8 weeks the frame of 8 weeks is from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in PANSS 5-factor Model</measure>
    <time_frame>Week 8</time_frame>
    <description>Mean change in PANSS 5-factor model from baseline at Week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in PANSS Symptom Scores</measure>
    <time_frame>Week 8</time_frame>
    <description>Mean change in PANSS symptom scores from baseline at Week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in PANSS Symptom Scores From Baseline at Each Visit</measure>
    <time_frame>Each Visit</time_frame>
    <description>Mean change in PANSS symptom scores from baseline at each Visit from baseline at week 8</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Blonanserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antipsychotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antipsychotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blonanserin</intervention_name>
    <description>Blonanserin tablets: 8 - 24mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.</description>
    <arm_group_label>Blonanserin</arm_group_label>
    <other_name>Lonasen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>Risperidone tablets: 2 - 6mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.</description>
    <arm_group_label>Risperidone</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject met Diagnostic and Statistical Manual of Mental Disorders(DSM)-IV-Text
             Revision(TR) criteria for a primary diagnosis of schizophrenia

          -  Patients are 18≤age＜65 years of age on the day when informed consent is obtained.

          -  Subject had a PANSS total score ≥70 and 120≥ at Screening

          -  Subject had a score ≥4 on the PANSS at Screening and Baseline.

          -  Subjects are willing and able to comply with study protocol including treatment in
             hospital.

          -  Subjects or their legal guardians have signed the written informed consent form.

        Exclusion Criteria:

          -  The subject was treatment with other Investigate product within 30 days.

          -  Subject had a history of treatment with long-acting drug for anti schizophrenia within
             56 days.

          -  Subject had a history of treatment with clozapine within 28 days.

          -  Subject With parkinson disease,etc
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niufan Gu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Anding Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Huilongguan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100096</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Sixth Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou Brain Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510170</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hebei Province Mental Health Center</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <zip>071000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Provincial Mental Hospital</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <zip>453002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Province Brain Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410007</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Brain Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuxi Mental Health Center</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shang Hai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xi'an Mental Health Center</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Anding Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300222</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kun Ming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <results_first_submitted>February 12, 2015</results_first_submitted>
  <results_first_submitted_qc>May 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 26, 2018</results_first_posted>
  <last_update_submitted>November 25, 2018</last_update_submitted>
  <last_update_submitted_qc>November 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blonanserin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Blonanserin</title>
          <description>Blonanserin:
Dosage Form: Tablet Dosage and Usage: 8~24mg/d ,b.i.d</description>
        </group>
        <group group_id="P2">
          <title>Risperidone</title>
          <description>Risperidone:
Dosage Form: Tablet Dosage and Usage: 2~6mg/d ,b.i.d</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131">the patient number of randomization for Blonanserin Group</participants>
                <participants group_id="P2" count="136">the patient number of randomization for Risperidone Group</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>267 subjects in participant flow, 3 subjects randomized and not treated, 2 subjects does not have baseline PANSS scale, 1 subject take Blonanserin, which IWRS's indicate he should take Risperidone and no PANSS scale collectted after first dose. Those 6 subjects excluded from Baseline Population. The Baseline population have 261 subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>Blonanserin</title>
          <description>Participants received 8-24mg tablet orally twice daily for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Risperidone</title>
          <description>Participants received 2-6mg tablet orally twice daily for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="128"/>
            <count group_id="B2" value="133"/>
            <count group_id="B3" value="261"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="261"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in PANSS(Positive and Negative Syndrome Scale) Total Score at Week 8</title>
        <description>Mean change in Positive and Negative Syndrome Scale total score from baseline to Week 8 at the end of treatment. PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. It have 30 evaluation items, which include 7 positive sub-scale, 7 negative sub-scale and 16 general psychopathology sub-scale on a score of 1 to 7. The total score is the sum of the 30 scale items. The minimum score is 30 and the maximum score is 210. Patient with PANSS total scores＜70 is the normal,but the scores＞120 is more serious.Change=(Week 8 Score - Baseline score)</description>
        <time_frame>From baseline to the end of study、week 8(day 56)or before other antipsychotic taken.</time_frame>
        <population>267 subjects in participant flow, 3 subjects randomized and not treated, 2 subjects does not have baseline PANSS scale, 1 subject take Blonanserin, which randomized to Risperidone group and no PANSS scale collected after first dose. Those 6 subjects excluded from Baseline Population. The Baseline population have 261 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Blonanserin</title>
            <description>Participants received 8-24mg tablet orally twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Participants received 2-6mg tablet orally twice daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS(Positive and Negative Syndrome Scale) Total Score at Week 8</title>
          <description>Mean change in Positive and Negative Syndrome Scale total score from baseline to Week 8 at the end of treatment. PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. It have 30 evaluation items, which include 7 positive sub-scale, 7 negative sub-scale and 16 general psychopathology sub-scale on a score of 1 to 7. The total score is the sum of the 30 scale items. The minimum score is 30 and the maximum score is 210. Patient with PANSS total scores＜70 is the normal,but the scores＞120 is more serious.Change=(Week 8 Score - Baseline score)</description>
          <population>267 subjects in participant flow, 3 subjects randomized and not treated, 2 subjects does not have baseline PANSS scale, 1 subject take Blonanserin, which randomized to Risperidone group and no PANSS scale collected after first dose. Those 6 subjects excluded from Baseline Population. The Baseline population have 261 subjects.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ITT analysis: At the end of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.59" spread="18.53"/>
                    <measurement group_id="O2" value="-33.56" spread="16.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PPS analysis: At the end of treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.71" spread="17.02"/>
                    <measurement group_id="O2" value="-36.31" spread="14.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA was employed to compare the changes of PANSS scores at week 8 relative to the baseline in these 2 groups. Least Squares Means for the differences in changes between the 2 groups (μ blonanserin - μ risperidone) and the two-sided 95% Confidence Interval were calculated in accordance with the main model.
H0: Compared with risperidone, blonanserin reduced more than 7.0 in mean change in PANSS total score from baseline at week 8 of treatment (μ blonanserin-μ risperidone&gt; 7.0).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The power is 80%, non-inferiority margin is 7.0.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Satisfaction with the non-inferiority criteria was determined by the upper limit of confidence interval. If the upper limit of 95% confidence interval was less than 7.0, then non-inferiority was concluded.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Study center and grouping as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>7.75</ci_upper_limit>
            <estimate_desc>This is ITT analysis data.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA was employed to compare the changes of PANSS total scores at end of treatment relative to the baseline in these 2 groups. LSMeans for the differences in changes between the 2 groups (μ blonanserin - μ risperidone) and the two-sided 95% Confidence Interval were calculated in accordance with the main model.
H0: Compared with risperidone, blonanserin reduced more than 7.0 in mean change in PANSS total score from baseline at week 8 of treatment (μ blonanserin-μ risperidone&gt; 7.0).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The power is 80%, non-inferiority margin is 7.0.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Satisfaction with the non-inferiority criteria was determined by the upper limit of confidence interval. If the upper limit of 95% confidence interval was less than 7.0, then non-inferiority was concluded.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Study center and grouping as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>6.65</ci_upper_limit>
            <estimate_desc>This is PPS analysis data.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in PANSS Subscale Score at the End of Treatment</title>
        <description>Mean Change in PANSS subscale score at the end of treatment at 8 weeks the frame of 8 weeks is from baseline</description>
        <time_frame>week 8</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in PANSS 5-factor Model</title>
        <description>Mean change in PANSS 5-factor model from baseline at Week 8</description>
        <time_frame>Week 8</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in PANSS Symptom Scores</title>
        <description>Mean change in PANSS symptom scores from baseline at Week 8</description>
        <time_frame>Week 8</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in PANSS Symptom Scores From Baseline at Each Visit</title>
        <description>Mean change in PANSS symptom scores from baseline at each Visit from baseline at week 8</description>
        <time_frame>Each Visit</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety analysis set (SS, the primary analysis set for safety evaluation) SS of this study included all randomized subjects who have received at least 1 dose of the trial drug.
The SS population have 130 subjects in Blonanserin group, 134 subjects in Risperidone group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Blonanserin</title>
          <description>Participants received 8-24mg tablet orally twice daily for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Risperidone</title>
          <description>Participants received 2-6mg tablet orally twice daily for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal foreign matter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>fever of unknown origin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>chicken pox</sub_title>
                <description>One subject (random number 234) in blonanserin group developed &quot;chicken pox&quot; and recovered after quarantine, symptomatic and supportive treatment; in the investigator's opinions, this case was unrelated to the study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Galactorrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="28" subjects_affected="21" subjects_at_risk="130"/>
                <counts group_id="E2" events="34" subjects_affected="22" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Vomit</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal liver function</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="130"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>sleepiness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="130"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Upperrespiratory tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Serum prolactin increase</sub_title>
                <counts group_id="E1" events="68" subjects_affected="68" subjects_at_risk="130"/>
                <counts group_id="E2" events="90" subjects_affected="90" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increase</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="130"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increase</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increase</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Lipid increase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Body weight increase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Transaminase increase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Blood potassium decrease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Poor appetite</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hyperlipidemina</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Extrapyramidal disorders</sub_title>
                <counts group_id="E1" events="71" subjects_affected="63" subjects_at_risk="130"/>
                <counts group_id="E2" events="41" subjects_affected="39" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="130"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Excitement</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="130"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="24" subjects_at_risk="130"/>
                <counts group_id="E2" events="25" subjects_affected="18" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="130"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Poor sleep quality</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Somnipathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Diffculty falling asleep</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="130"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Stuffy nose</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Expectoration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="130"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.HuafangLi</name_or_title>
      <organization>Shang Hai Mental health center</organization>
      <phone>13641625395</phone>
      <email>lhlh_5@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

